Silence Therapeutics Ownership | Who Owns Silence Therapeutics?
Silence Therapeutics Ownership Summary
Silence Therapeutics is owned by 35.30% institutional investors, 24.38% insiders, and 40.33% retail investors. Tcg crossover management is the largest institutional shareholder, holding 6.42% of SLN shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 1.36% of its assets in Silence Therapeutics shares.
SLN Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Silence Therapeutics | 35.30% | 24.38% | 40.33% |
| Sector | Healthcare Stocks | 42.54% | 10.83% | 46.63% |
| Industry | Biotech Stocks | 45.22% | 10.75% | 44.04% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Tcg crossover management | 3.03M | 6.42% | $15.74M |
| Artal group | 2.78M | 6.32% | $52.81M |
| Siren | 2.91M | 6.16% | $15.11M |
| Redmile group | 2.16M | 4.58% | $11.24M |
| Lombard odier asset management (usa) | 1.84M | 3.91% | $7.12M |
| Morgan stanley | 1.21M | 2.56% | $6.27M |
| Vivo capital | 1.11M | 2.34% | $5.74M |
| Nantahala capital management | 1.04M | 2.21% | $5.41M |
| Frazier life sciences management | 970.13K | 2.05% | $5.03M |
| Nextech invest | 952.40K | 2.02% | $4.94M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| M28 capital management lp | 185.10K | 1.41% | $960.67K |
| Artal group | 2.78M | 1.35% | $52.81M |
| Redmile group | 2.16M | 1.09% | $11.24M |
| Nextech invest | 952.40K | 1.06% | $6.55M |
| 5am venture management | 476.20K | 0.91% | $2.47M |
| Tcg crossover management | 3.03M | 0.77% | $15.74M |
| Nextech invest | 952.40K | 0.75% | $4.94M |
| Siren | 2.91M | 0.59% | $15.11M |
| Lombard odier asset management (usa) | 1.84M | 0.48% | $7.12M |
| Vivo capital | 1.11M | 0.46% | $5.74M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Ubs group | 307.36K | 0.00% | 78.85K |
| Citadel advisors | 116.76K | 0.00% | 74.08K |
| Ikarian capital | 900.78K | 0.13% | 27.22K |
| Boothbay fund management | 279.64K | 0.02% | 27.22K |
| Goldman sachs group | 22.64K | - | 22.64K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Lombard odier asset management (europe) | - | - | -2.24M |
| Janus henderson group | - | - | -1.09M |
| Deep track capital, lp | - | - | -1.00M |
| Polar capital | - | - | -1.00M |
| Eventide asset management | - | - | -640.00K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Hrt financial lp | 10.89K | 0.00% | 10.89K | $56.00K |
| Ehp funds | 10.67K | 0.05% | 10.67K | $55.39K |
| Rockefeller capital management | 45.00 | - | 45.00 | $234.00 |
Sold Out
| Holder | Change |
|---|---|
| Eversource wealth advisors | -10.00 |
| Lazard asset management | -60.00 |
| Values first advisors | -3.09K |
| Advisors preferred | -5.32K |
| Quarry lp | -6.00K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | 53 | -7.02% | 16,670,893 | -15.69% | 35 | 18.12% | 21 | -8.70% | 16 | -15.79% |
| Jun 30, 2025 | 56 | -6.67% | 19,736,025 | -7.96% | 13 | 6.08% | 22 | -8.33% | 19 | -24.00% |
| Mar 31, 2025 | 60 | -9.09% | 21,913,755 | -11.60% | 15 | 4.95% | 23 | -39.47% | 25 | 92.31% |
| Dec 31, 2024 | 61 | -14.08% | 21,582,466 | -23.46% | 15 | 0.42% | 35 | -5.41% | 12 | -20.00% |
| Sep 30, 2024 | 70 | - | 28,105,051 | 3.61% | 60 | 1.79% | 37 | 12.12% | 14 | -26.32% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 640.00K | 1.36% | - |
| Polar Capital Biotech S Inc | 467.15K | 0.99% | -532.85K |
| International Biotechnology Ord | 444.00K | 0.94% | - |
| MEDICAL BioHealth EUR Acc | 295.00K | 0.62% | - |
| iShares Biotechnology ETF | 140.48K | 0.30% | - |
| T. Rowe Price Health Sciences | 95.65K | 0.20% | 95.65K |
| BIT Biotech Opportunities S | 92.43K | 0.20% | -14.87K |
| Tema Obesity & Cardiometabolic ETF | 76.77K | 0.16% | - |
| Galileo - Biotech Innovation Fund S USD | 58.65K | 0.12% | - |
| RIM Global Bioscience EUR | 57.86K | 0.12% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jul 31, 2025 | Griffiths Richard Ian | - | Buy | $88.63K |
| Aug 01, 2025 | Griffiths Richard Ian | - | Buy | $24.77K |
| Jul 29, 2025 | Griffiths Richard Ian | - | Buy | $90.27K |
| Jul 30, 2025 | Griffiths Richard Ian | - | Buy | $54.79K |
| Jul 22, 2025 | Griffiths Richard Ian | - | Buy | $17.72K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q3 | 9 | - |
| 2025 Q2 | 37 | - |
| 2025 Q1 | 13 | - |
SLN Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools